Bioventus (BVS) Cash from Financing Activities (2020 - 2026)

Bioventus (BVS) has 7 years of Cash from Financing Activities data on file, last reported at -$23.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 2543.93% year-over-year to -$23.1 million; the trailing twelve-month figure through Mar 2026 stood at -$86.2 million (down 74.59% YoY), and the FY2025 full-year result was -$62.1 million, down 13.85% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$23.1 million, up from -$28.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $50.7 million in Q4 2022 and bottomed at -$62.2 million in Q3 2023.
• The 5-year median for Cash from Financing Activities is -$4.2 million (2024), against an average of -$6.1 million.
• The widest annual swing landed in 2022, when Cash from Financing Activities surged 1265.53%; it then sank 306007.14% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$5.4 million in 2022, then soared by 99.74% to -$14000.0 in 2023, then tumbled by 306007.14% to -$42.9 million in 2024, then soared by 33.62% to -$28.4 million in 2025, then rose by 18.64% to -$23.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$23.1 million (Q1 2026), -$28.4 million (Q4 2025), and -$20.0 million (Q3 2025), per Business Quant data.

Peer Comparison